Sharemaestro Newsreel

HTFL Maintained by Wells Fargo -- Price Target Raised to $39

Here's Why Foghorn Therapeutics Inc. (FHTX) is a Great Momentum Stock to Buy

Quest Diagnostics (DGX) Is Up 2.29% in One Week: What You Should Know

Momentum investing revolves around the idea of following a stock's recent trend in either direction. In "long context," investors will be essentially be "buying high, but hoping to sell even higher." With this methodology, taking advantage of trends in a stock's price is key; …

CABA Maintained by Wells Fargo -- Price Target Lowered to $3.00

Wells Fargo has maintained an Equal-Weight rating for Cabaletta Bio Inc (CABA) but lowered its price target from $4.00 to $3.00, reflecting a cautious outlook. The company's GF Score™ of 34/100 indicates significant weaknesses in profitability and growth, despite strengths in financial stability and …

AVAH Q2 Earnings Call Highlights Higher Growth Targets

What Makes Pulmonx Corporation (LUNG) a Strong Momentum Stock: Buy Now?

Pulmonx Corporation (LUNG) has been identified as a strong momentum stock by Zacks Equity Research, boasting a Momentum Style Score of B and a Zacks Rank of #2 (Buy). The company has shown significant short-term and long-term price performance, outperforming both its industry and …

Reflecting On Healthcare Technology Stocks’ Q2 Earnings: GoodRx (NASDAQ:GDRX)

Aquamarine Financial (ORMP) discloses 6.04% Oramed ownership in 13G/A

Aquamarine Financial (Cayman) Ltd has reported a beneficial ownership of 2,512,175 shares in Oramed Pharmaceuticals Inc., which constitutes 6.04% of the common stock as of June 30, 2026. The filing, an amended Schedule 13G/A, indicates that Aquamarine holds sole voting and sole dispositive power …

Scienture Holdings Q2 non-GAAP EPS of -$0.07, revenue of $0.34M

* Scienture Holdings, Inc. press release [https://seekingalpha.com/pr/20619685-scienture-reports-q2-2026-results-with-approximately-510-percent-sequential-revenue-growth] (SCNX [https://seekingalpha.com/symbol/SCNX]): Q2 Non-GAAP EPS of -$0.07. * Revenue of $0.34M. * Net loss for Q2 2026 narrowed 58% YoY to $2.82M from $6.72M in Q2 2025. * Gross profit was $0.34M with a gross margin of …

Immix Biopharma (IMMX) gains 5.6% stake holder led by Eventide Asset Management

Eventide Asset Management, LLC, through its Eventide Healthcare & Life Sciences Fund, has reported a beneficial ownership of 3,891,019 shares of Immix Biopharma (IMMX) common stock, representing a 5.6% stake. This Schedule 13G filing indicates that Eventide holds sole voting and dispositive power over …

What is driving nursing shortages? It's 'not a supply problem'

Meghan Fitzgerald, Columbia Professor, Grey Ghost Capital Private Equity Investor and on the board of Tenet Healthcare joins Yahoo Finance's Julie Hyman to explain why the U.S. healthcare crisis stems from nurse retention and burnout rather than a labor supply shortage. Video Transcript 00:00 …

[6-K] Valneva SE Current Report (Foreign Issuer)

Valneva SE (VALN) filed a Form 6-K Current Report with the SEC on August 14, 2026, which incorporated a press release dated the same day. This report indicates the company's ongoing compliance with foreign private issuer reporting requirements and includes information relevant to its …

Brad Bickham Returns as Addus HomeCare Interim COO

Addus HomeCare Corporation announced that Heather Dixon, president and chief operating officer, has left the company. Brad Bickham, former president and chief operating officer, will return as interim COO for one year, effective immediately. CEO Dirk Allison expressed gratitude for Dixon's contributions and confidence …

Is Alpha Tau Medical’s (DRTS) Steepening Loss Curve Reframing Its High-Risk Innovation Strategy?

Alpha Tau Medical (DRTS) reported a significant widening of its net loss to US$68.75 million in the first half of 2026, up from US$18.81 million a year prior, leading to increased concerns about its funding risk. Despite the company's focus on clinical progress for …

Eventide Asset Management (OVID) discloses 6.3% ownership stake in Ovid Therapeutics

Fate Therapeutics Initiates Potentially Registrational Trial of Off-the-Shelf CAR T-Cell Therapy FT819 for Lupus Nephritis

Fate Therapeutics has started RECLAIM-LN, a Phase 2 registrational trial for its off-the-shelf CAR T-cell therapy FT819, targeting refractory lupus nephritis. This follows positive Phase 1 safety and efficacy data. The trial, developed with FDA interaction, aims to enroll 53 patients, with preliminary data …

ALNY Maintains Equal-Weight by Wells Fargo -- Price Target Lowered to $256

Wells Fargo has maintained an Equal-Weight rating for Alnylam Pharmaceuticals (ALNY), lowering its price target from $316.00 to $256.00, an 18.99% decrease. Despite this, GuruFocus indicates ALNY is significantly undervalued at $223.22 compared to its GF Value™ of $528.81, showing a 57.8% undervaluation and …

Aytu BioPharma (AYTU) investor and foundation each report 4.99% beneficial stake

An investor, Laurence W. Lytton, and the Lytton-Kambara Foundation have each reported a 4.99% beneficial ownership stake in Aytu BioPharma (AYTU), according to a recent Schedule 13G/A filing. Each party beneficially owns 545,946 shares, consisting of common stock and warrants, with all voting and …

StemPoint group (XLO) discloses 9.5% Xilio Therapeutics stake via warrants

StemPoint Capital LP, StemPoint Capital Management GP LLC, and Michelle Ross have collectively reported a 9.5% beneficial ownership in Xilio Therapeutics, Inc. (XLO) through an SEC Schedule 13G/A filing. Their stake comprises 628,866 shares of common stock, primarily derived from pre-funded, Series A, and …

Wells Fargo & Company Lowers Cabaletta Bio (NASDAQ:CABA) Price Target to $3.00

Wells Fargo & Company has lowered its price target for Cabaletta Bio (NASDAQ:CABA) from $4.00 to $3.00, while maintaining an "equal weight" rating, suggesting a potential upside of 12.57%. Analyst opinions are varied, with MarketBeat reporting a "Moderate Buy" consensus and a $15.33 average …

MeiraGTx (NASDAQ:MGTX) Given New $27.00 Price Target at Royal Bank Of Canada

West Pharmaceutical (WST) Upgraded to Buy: Here's Why

West Pharmaceutical (WST) has been upgraded to a Zacks Rank #2 (Buy) due to an upward trend in its earnings estimates. This upgrade suggests a positive outlook for the company's underlying business and could lead to a favorable impact on its stock price. The …

Is EW Stock Worth Buying as Growth Clashes With a Premium Valuation?

Edwards Lifesciences Corporation EW is entering the second half of 2026 with faster structural heart growth and better operating leverage. Second-quarter revenues rose 13.6% to $1.74 billion, while adjusted earnings increased 16.4% to 78 cents per share. The question is whether that momentum warrants …

Eton Pharmaceuticals: No Reason Pharma Can't Deliver More Great Earnings Like These

Short Interest in Indaptus Therapeutics, Inc. (NASDAQ:INDP) Declines By 64.1%

Short interest in Indaptus Therapeutics (NASDAQ:INDP) dramatically decreased by 64.1% in July, totaling 93,141 shares as of July 31st. Despite beating consensus EPS estimates for the quarter, the stock trades near its one-year low, and analyst sentiment remains negative with an average "Sell" rating. …

Reasons to Hold Hinge Health Stock in Your Portfolio for Now

Hinge Health HNGE is well-positioned for sustained growth, driven by robust revenue growth, expanding opportunities in Migraine and gastrointestinal (GI) care and a scalable AI-powered MSK platform. The raised 2026 outlook, broader enterprise reach and growing sales pipeline further support the growth outlook. However, …

Lite Strategy, Inc. (NASDAQ: LITS) Share Price, LITS Stock News, LITS Share Price & Updates

This article provides stock information for Lite Strategy, Inc. (NASDAQ: LITS), detailing its share price, recent changes, active day range, and 52-week range. It also includes fundamental data such as previous close, market cap, volume, and revenue. The content emphasizes that the information is …

BridgeBio Stock Has Soared 29% in Just 3 Months. Here's Why Wall Street Thinks It Could Go Even Higher.

One of the more high-flying stocks in the U.S. biotech sector these days is genetic-disease-focused BridgeBio Pharma (NASDAQ: BBIO). That's due almost entirely to the outperformance of its Attruby heart medication. If the generally bullish analyst sentiment on the company is anything to go …

SOLV Plans Health Information Systems Business Spinoff to Drive Growth

Solventum SOLV plans to separate its Health Information Systems (HIS) business as part of its portfolio optimization strategy. The move is expected to sharpen the company's focus on its core MedSurg and Dental Solutions businesses while allowing HIS to pursue its growth opportunities as …

HAE Stock Gains on Q1 Earnings & Revenue Beat, Fiscal '27 View Up

Haemonetics Corporation HAE posted first-quarter fiscal 2027 adjusted earnings of $1.14 per share, up 3.6% year over year. The figure beat the Zacks Consensus Estimate by 6.5%. On a GAAP basis, earnings per share were 72 cents compared with 70 cents in the prior-year …

Ascendis Pharma Reports Solid Yorvipath Quarter; Yuviwel Off to Strong Start, RBC Says

Ascendis Pharma's (ASND) Q2 results showed a solid rebound for Yorvipath, while the early launch of Yuviwel in achondroplasia is progressing well, RBC Capital Markets said in a Thursday note.According to the note, Yorvipath revenue rose to 252 million euros ($291.8 million) from Silver …

Inovio Pharmaceuticals Inc. stock outperforms competitors on strong trading day

Inovio Pharmaceuticals Inc. (INO) shares surged 21.10% to $1.09 on Friday, outperforming the broader market as the NASDAQ Composite Index and Dow Jones Industrial Average both experienced declines. This marked the fifth consecutive day of gains for Inovio's stock, despite a generally rough trading …

Should You Continue to Hold ACHC Stock at an 18.17X P/E Valuation?

Acadia Healthcare Company, Inc.ACHC benefits from strong long-term demand for behavioral health services. The company is expanding its network through joint ventures, de novo facilities and bed additions. Shares of ACHC have surged 113.1% year to date, significantly outperforming the industry's 13.2% growth during …

BridgeBio Pharma's Transition to Rare Disease 'Commercial Powerhouse' On Track, RBC Says

BridgeBio Pharma's (BBIO) transition into a rare disease "commercial powerhouse" is on track and poised to accelerate, RBC Capital Markets said in a Friday note.The company's Attruby drug is gaining traction in first-line treatment settings, while the market for the drug Silver Upgrade to …

bioAffinity Technologies closes $4M private placement By Investing.com

bioAffinity Technologies (NASDAQ:BIAF) has successfully completed a private placement, raising approximately $4.0 million. The placement involved pre-funded warrants to purchase over 8.4 million shares of common stock, along with accompanying standard warrants. The funds raised will support the company's operations, including the development of …

Denali Therapeutics CEO Ryan J. Watts Donates 32,220 Shares to Donor Advised Fund

Denali Therapeutics Inc. CEO, Ryan J. Watts, donated 32,220 shares of common stock to a donor-advised fund on August 12, 2026, as disclosed in an SEC Form 4 filing. This charitable gift, valued at $0, was reported on August 14, 2026. Following the donation, …